drugset
drugset / Trial / NCT05144009

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

NCT05144009 ↗

Phase 2 Terminated 41 enrolled ADC Therapeutics S.A.
Non-randomizedSequentialOpen-labelTreatment

Summary

The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.

Timeline

Start
2022-06-21
Primary completion
2024-01-22
Completion
2024-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Loncastuximab Tesirine Other / unclassified 75 ug/kg Intravenous
Subject Loncastuximab Tesirine Other / unclassified 150 ug/kg Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 1400 mg Intravenous

Indications

diffuse large B-cell lymphoma